Intervju med vd Andreas Bhagwani 23 april 2025
23 April, 2025
Intervju med vd Andreas Bhagwani om delårsrapporten för första kvartalet, ny order och förbättringar i produktionen. Länk till intervjun
ABOUT NANOLOGICA
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.
Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
NLAB Saga®
A NEW GENERATION SILICA FOR PREPARATIVE CHROMATOGRAPHY
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
News
Nanologica AB Receives Order Worth USD 180,000 from New Customer in China
23 April, 2025
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in China. The customer is a large pharmaceutical manufacturer, and the order relates to evaluation of NLAB Saga® on a production scale. The order, which is worth USD 180,000, will be delivered during the second quarter. ”This is
Interim Report Q1 2025
16 April, 2025
FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK 9,241 thousand (15,331) Loss after tax amounted to SEK 10,171 thousand (16,734) Earnings per share before and after dilution were SEK -0.12 (-0.46) Cash and cash equivalents per 31 March 2024 amounted to SEK 28,348
Listen to our team talk about Nlab Saga®
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Presentation of Nanologica
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.